Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Yea... ( NEW BRUNSWICK N.J. Jan. 24 2012 /- Jo...)

Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:

Date:1/24/2012

NEW BRUNSWICK, N.J., Jan. 24, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%. Domestic sales declined 3.4%, while international sales increased 10.2%, reflecting an operational increase of 10.4% and a negative currency impact of 0.2%. Worldwide sales for the full-year 2011 were $65.0 billion, an increase of 5.6% versus 2010. Operational sales increased 2.8% and the positive impact of currency was 2.8%. Domestic sales declined 1.8%, while international sales increased 12.4%, reflecting operational growth of 7.0% and a positive currency impact of 5.4%.

Net earnings and diluted earnings per share for the fourth quarter of 2011 were $0.2 billion and $0.08, respectively. Fourth-quarter 2011 net earnings reflect after-tax charges of $2.9 billion, which include product liability expenses, the net impact of litigation settlements, costs associated with the DePuy ASR™ Hip recall program, and an adjustment to the value of a currency option and costs related to the planned acquisition of Synthes, Inc. Fourth-quarter 2010 net earnings included after-tax charges of $922 million representing product liability expenses, the net impact of litigation settlements, and costs associated with the DePuy ASR™ Hip recall program. Excluding these special items for both periods, net earnings for the current quarter were $3.1 billion and diluted earnings per share were $1.13, representing increases of 9.3% and 9.7%, respectively, as compared to the same period in 2010.*

Net earnings and diluted earnings per share for the full-year 2011 were $9.7 billion and $3.49, respectively. Full-year 2011 net earnings reflect after-tax charges of $4.2 billion, which include product liability expenses, the net impact of litigation settlements, a previ
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
3. Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
4. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
5. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
6. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
7. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
8. EF Johnson Technologies Announces Third Quarter Results
9. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allegations of Off-Label Promotion of Topamax

Post Your Comments:

(Date:5/23/2013)... , May 23, 2013 Israel Brain ... 2013 , Israel,s 1 st ... 14 th -15 th in Tel Aviv ... innovative city in the world by the Wall Street ... BrainTech Israel 2013 will showcase the latest breakthroughs in ...

(Date:5/23/2013)... , May 23, 2013 EarlySense, ... today that the prize for ,Best Novel Idea, at ... Medical Emergency Teams International Conference, hosted this year in ... awarded to a clinical research team studying the impact ... Hospital in Los Angeles . The ...

(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ( ... FDA, Health Canada and CE ( Europe ... Glasgow Science Centre in Scotland , ... the SynCardia temporary Total Artificial Heart powered ... $3 million Bodyworks Exhibition, one of the most advanced ...

Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2 Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3 Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3

[0] Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference [0] Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference [0] Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition

... -- , - Cipralex Better Tolerated and at ... A/S announces new study data published today in ... (escitalopram) was superior to duloxetine in the acute,treatment ... was,at least as efficacious in long-term treatment(1). The ...

... for CPX-1 presented at ASCO confirm safety findings,and ... patients with,colorectal and other types of cancer., PRINCETON, ... positive safety and efficacy results from,its Phase I ... with heavily pre-treated, advanced solid,tumors. Results were presented ...

Cached Medicine Technology:Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 2 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 3 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 4 Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression 5 Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing 2 Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing 3

Newly Published Data Demonstrates Superiority of Cipralex Over,Duloxetine for Acute Treatment of Depression Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing

(Date:5/23/2013)... News) -- A modified version of the polio ... preliminary research suggests. Scientists at Duke Cancer ... PVSRIPO, uses an engineered form of the virus ... cancer cells. The therapy shows promise in the ... brain tumor, they said. "These early results ...

(Date:5/23/2013)... (May 23, 2013)Don,t doubt it when a woman harried ... remembering things. A new study published online in ... Society (NAMS), helps confirm with objective tests that what ... In the past, some studies showed that hot flashes ... studies showed that, even though there was a relationship ...

(Date:5/23/2013)... PA (PRWEB) May 23, 2013 ... Teaching Site, offering a comprehensive babysitting training course for ... program was developed by Indianapolis pediatrician Dr. Patricia Keener ... the care of an adult sitter who didn’t know ... well-rounded youth development program with a medical basis that ...

(Date:5/23/2013)... anti-cancer drug about to be tested in a clinical ... possible treatment for Alzheimer,s disease has failed to work ... Alzheimer,s patients, according to results of a study by ... professor of neuroscience affiliated with the Evelyn F. and ... Florida, emphasized the importance of verifying promising research results ...

(Date:5/23/2013)... The Rottenstein Law Group LLP, a New York-based nationwide ... Information Center at http://www.rotlaw.com/tylenol , dedicated to issues ... considering filing lawsuits. , The painkiller Tylenol (acetaminophen) ... according to a 2009 report from the U.S. Food ... FDA warned consumers against using more than the recommended ...

Breaking Medicine News(10 mins):Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2 Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2 Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3 Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2 Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3 Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2

[0] Modified Polio Virus May Help Fight Brain Tumors, Study Suggests [0] It's not your imagination: Memory gets muddled at menopause [0] Susquehanna Health Offers Safe Sitter Course for Tweens and Teens [0] Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study [0] Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center

... , ... new market research report is available in its catalogue: ... , http://www.reportlinker.com/p0166825/Antibiotic-Resistance-and-Antibiotic-Technologies-Global-Markets.html , Provide an in-depth ... antibiotics technologies , Offer an analysis of antibiotics resistance ...

... , WEDNESDAY, Dec. 2 (HealthDay News) -- In the ... patients in the United States have improved modestly, a ... more than 100,000 patients diagnosed with stage 4 non-small ... patient information was in the U.S. National Cancer Institute,s ...

... have metabolic syndrome, study finds , WEDNESDAY, Dec. 2 ... overweight college football players from being at higher risk ... disease, a new study suggests. , Researchers studied linemen ... obese. Of those, 42 percent had metabolic syndrome, a ...

... Va., Dec. 2 By now, most people have heard of ... the latest product on the market is now available at the ... at the amazingly low price of $14.99. , "This new product ... very low price, before making a bigger investment in a smokeless ...

... MONTREAL, Dec. 2 /PRNewswire/ - As part of its continued ... part of Pfizer, has pledged more than 40 million international ... Hemophilia (WFH). This is the largest donation ever made to ... impact to advance the WFH,s goals. , "This donation will ...

... , KNOXVILLE, Tenn., Dec. 2 TeamHealth ( www.teamhealth.com ... of Naples-based Emergency Physicians of Naples, LLC (EPN). Since ... Healthcare System to staff the emergency facilities at the Downtown ... EPN also provides the staffing for two stand-alone urgent care ...

Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets Gains Made in Lung Cancer Survival Oversized College Football Players May Face Heart Risks A Smokeless Holiday Season? Premium Electronic Cigarette Announces New Disposable Smokeless Cigarette Product The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH TeamHealth Acquires Emergency Physicians of Naples, LLC

... Ultra Strep A Test is a color ... DLT uses antibody labeled color particles coated ... device. DLT allows greater sensitivity than the ... In the test procedure, a throat swab ...

... Fertell test is an easy to use, one ... reserve by means of determining the amount of ... sample. The test is performed two days after ... menstrual cycle) and is similar in design and ...

... The Cholestech GDX System delivers an unmatched combination ... ideal solution for assessing and monitoring a patient's ... demo, click here ., ,The CLIA-waived Cholestech ... A1C results in less than 5 minutes. The ...

... The Cholestech LDX System, using patented, ... plus glucose and ALT in only 5 ... new ALT test, you can get immediate ... measurement capabilities is not the only advantage ...

Medicine Products:

OSOM Ultra 25 Strep A Fertell Female Fertility Test Cholestech GDX System LDX Analyzer